Literature DB >> 25743715

Adalimumab trough levels and response to biological treatment in patients with inflammatory bowel disease: a useful cutoff in clinical practice.

Giorgia Bodini1, Edoardo G Giannini1, Edoardo V Savarino2, Vincenzo Savarino1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 25743715     DOI： 10.1038/ajg.2015.10

Source DB:  PubMed          Journal:  Am J Gastroenterol        ISSN： 0002-9270            Impact factor:   10.864


× No keyword cloud information.
  3 in total

Review 1.  Pharmacokinetics in IBD: ready for prime time?

Authors:  Xavier Roblin; Melanie Rinaudo; Miles Peter Sparrow; Amelie Moreau; Jean Marc Phelip; Christian Genin; Dominique Lamarque; Stephane Paul
Journal:  Curr Drug Targets       Date:  2014       Impact factor: 3.465

2.  Association between pharmacokinetics of adalimumab and mucosal healing in patients with inflammatory bowel diseases.

Authors:  Xavier Roblin; Hubert Marotte; Melanie Rinaudo; Emilie Del Tedesco; Amelie Moreau; Jean Marc Phelip; Christian Genin; Laurent Peyrin-Biroulet; Stephane Paul
Journal:  Clin Gastroenterol Hepatol       Date:  2013-07-23       Impact factor: 11.382

3.  Development of an algorithm incorporating pharmacokinetics of adalimumab in inflammatory bowel diseases.

Authors:  Xavier Roblin; M Rinaudo; E Del Tedesco; J M Phelip; C Genin; L Peyrin-Biroulet; S Paul
Journal:  Am J Gastroenterol       Date:  2014-06-10       Impact factor: 10.864
  3 in total
  2 in total

1.  Response to Bodini et al.

Authors:  S Paul; X Roblin
Journal:  Am J Gastroenterol       Date:  2015-03       Impact factor: 10.864

2.  Lower adalimumab trough levels are associated with higher bowel wall thickness in Crohn's disease.

Authors:  Bella Ungar; Zohar Ben-Shatach; Limor Selinger; Alona Malik; Ahmad Albshesh; Shomron Ben-Horin; Rami Eliakim; Uri Kopylov; Dan Carter
Journal:  United European Gastroenterol J       Date:  2019-09-19       Impact factor: 4.623
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.